Form 4: Mineralys Therapeutics Director Transfers Stock Options to Catalys Pacific Fund, LP

Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, Inc., transferred 32,900 stock options to Catalys Pacific Fund, LP on February 13, 2025.

Summary

• On February 13, 2025, Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, Inc. (MLYS), transferred 32,900 stock options to Catalys Pacific Fund, LP.
• The stock options have an exercise price of $10.20 and expire on February 13, 2035.
• The options vest in 12 substantially equal monthly installments following the grant date.
• Slingsby disclaims beneficial ownership of the shares held by Catalys Pacific Fund, LP, except to the extent of any pecuniary interest.
• Catalys Pacific Fund, LP now directly holds 32,900 stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of a stock option transfer. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the ownership changes of Mineralys Therapeutics' securities. It's common for directors and significant shareholders to manage their equity positions, and this transfer to Catalys Pacific Fund, LP is part of that process.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, Brian Taylor Slingsby, Catalys Pacific Fund, Stock Options, Beneficial Ownership, Form 4, Director, 10% Owner